Alvotech (ALVO) on Monday said that the European Commission has approved AVT03 as a biosimilar to Prolia and Xgeva (denosumab). Denosumab is widely used to manage osteoporosis and to prevent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results